203 Users Online
Zoonotic Disease Market Segmented By disease type that is Viral, Bacterial, Fungal, Nematode with drug class that is Antiviral, Antibiotic and antibacterial, Antifungals
Zoonotic disease is communicable diseases spread between humans and faunas by direct contact or through air, water, vectors such as mosquitoes, flea etc., and consumption of contaminated meat, milk or close contact. The causative agent includes virus, bacteria, worms, fungus, protozoa, pests and other parasites.
Zoonotic disease can be mild to fatal, depending upon the pathogen, pathogenesis and treatment, and may even lead to death. According to the World Health Organization (WHO), over one billion infections and millions of deaths happen due to zoonotic diseases every year, which constitutes 60% of the total emerging infectious diseases, worldwide.
The symptoms may take a window period to develop, although the infection can still spread. The symptoms range from gastrointestinal issues, flu-like symptoms, skin infections and others. The rising population and compromised hygiene standards have resulted in a surge of zoonotic diseases including malaria, lyme disease, salmonellosis, tuberculosis, anthrax, rabies and many others.
Zoonotic disease diagnosis is done by microbiological laboratory diagnostics such as immunohistochemistry, polymerase chain reaction (PCR), microscopic examinations of tissue fluid or samples, clinical recognition epidemiology studies and other diagnosis.
The global zoonotic disease market is poised to grow due to the population bloom, massive spread of infections and increasing pet care, creating a huge demand for diagnostics and medications. Coronavirus or COVID-19 pandemic has rocketed zoonotic disease market with the looming infections and massive death tolls, globally.
The diagnostics, medication and vaccine development is accelerating with the fastest pace, thus leveraging the zoonotic disease market furthermore.
The global zoonotic disease market is driven by the rapid population boom and movement massive urbanization, close contact with animals, rearing and pet zoonotic diseases. The global nutrition transition, increasing per capita income toward animal protein leading to massive reliance on animals livestock and escalating global ‘wet markets’.
The crowded environment, compromised hygiene, climate and habitat changes, animals rearing and lack of awareness are also leading to a surge in zoonotic diseases.
The progressing healthcare, R&D and diagnostics, rising animal healthcare clinics due to the increasing pet-owning, are fuelling the zoonotic disease market growth. However, certain constraints decelerate the global zoonotic disease market including lack of awareness, need for investments into R&D and healthcare to meet the elevating demands of zoonotic diseases.
Although, the overall global zoonotic disease market is anticipated to grow with the increasing infestation of zoonotic disease, advancing R&D and healthcare. The coronavirus diagnosis and medication have propelled the global zoonotic disease market furthermore. The key players of the zoonotic disease market are developing novel medications, improved medicated veterinary feed, vaccines and diagnostics for zoonotic diseases.
|By disease type||
|By drug class||
The global zoonotic disease market is growing lucratively with population boom, increasing zoonotic disease and rising pet healthcare facilities. By disease type, viral segments lead the zoonotic disease type with the massive burden and global research and healthcare expenditure of coronavirus, rabies, influenza and west nile virus, chikungunya virus.
By drug class, antiviral dominates the zoonotic disease drug classes with its massive antiviral demand for swine flu, bird flu, influenza and coronavirus. The major antivirals include oseltamivir zanamivir, ribavirin and others. By end-users, hospitals dominate the given segment of the zoonotic disease market due to their innovative and advanced healthcare infrastructure, highly skilled medical staff, affordable and diverse services.
North America leads the global zoonotic disease market with the major attributions from its advanced healthcare and expenditures, rising numbers of pet owners and animal healthcare facilities, advancing R&D for novel therapies. Europe holds the second largest market with its advanced research and healthcare infrastructure, and consistently growing veterinary healthcare.
Asia-pacific zoonotic disease market is emerging significantly with the surging cases of zoonotic diseases due to poor sanitary and hygiene standards, and dearth of safe drinking water. Although, biopharma R&D and healthcare facilities of China, India and Japan are advancing for zoonotic diseases diagnosis and therapy.
Latin America zoonotic disease market is growing gradually with the increasing infections, driven by high population density and poor sanitation. MEA &Africa zoonotic disease market is experiencing moderate growth with the improving veterinary healthcare and surging cases due to poor hygiene.
The key players of global zoonotic disease market include Cadila Pharmaceuticals, Novartis, Johnson & Johnson, AstraZeneca, Pfizer, Virbac, Sanofi, Bayer, GlaxoSmithKline plc., Roche, Zoetis, Ceva Logistics, BioCryst Pharmaceuticals, Emergent BioSolutions and many others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.